Novo Nordisk's Etavopivat Hits Phase 3 Endpoints for Sickle Cell Disease, Paving Way for H2 2026 Regulatory Submission
NVO is trading near its 52-week low of $35.12 (15% above the low).
Summary
Novo Nordisk announced positive topline Phase 3 results for etavopivat in sickle cell disease, meeting both co-primary endpoints and demonstrating significant reductions in vaso-occlusive crises and improved haemoglobin response, with regulatory submission planned for the second half of 2026.
Key Events · Product Development and Regulatory · NVO
-
Etavopivat Achieves Phase 3 Success
Topline results from the HIBISCUS trial showed etavopivat met both co-primary endpoints, significantly reducing vaso-occlusive crises (27% reduction) and improving haemoglobin response (48.7% vs 7.2% placebo) in sickle cell disease patients.
-
Regulatory Submission Planned
Novo Nordisk intends to submit etavopivat for its first regulatory approval in the second half of 2026, following these positive trial outcomes.
-
Addresses High Unmet Need
Etavopivat targets sickle cell disease, a debilitating and life-threatening condition affecting millions globally, where current therapeutic options are limited.
-
Pipeline Validation
This success validates the 2022 acquisition of Forma Therapeutics, from which etavopivat originated, strengthening Novo Nordisk's rare disease pipeline.
Analysis · NVO · Life Sciences
Novo Nordisk announced highly positive Phase 3 results for etavopivat, a drug acquired through the Forma Therapeutics acquisition, in treating sickle cell disease (SCD). Meeting both co-primary endpoints with a significant reduction in vaso-occlusive crises and improved haemoglobin response is a major clinical success. This development is critical for patients with SCD, a severe and life-shortening disease with limited treatment options. The planned regulatory submission in the second half of 2026 positions etavopivat as a potential new blockbuster drug, validating Novo Nordisk's strategic pipeline investments and opening a significant new market opportunity.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $40.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $181.7B. The 52-week trading range was $35.12 to $81.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.